Prior MTB effect-on-protein-function classes are a proxy reference, not oncogenicity ground truth.
These checks assess whether the evidence supports a reproducible investigation. A source-checked score alone does not meet these requirements.
Release 2026-09-30-e37e3ab1284d · Evidence verified: Not verified
Exact outcomes, predictions, identifiers and evaluator are connected.
Missing or unresolved evidence
Verified: Not verified
Replay evidence includes annotations and an assessment of dependence. Unknown independence permits descriptive analysis only.
Missing or unresolved evidence
Verified: Not verified
A pinned recipe describes the inputs, environment and resource requirements.
Missing or unresolved evidence
Verified: Not verified
Separate data and exposure records support an independent test.
Missing or unresolved evidence
Verified: Not verified
Readiness describes the evidence in this release. Availability on your computer is checked separately when an investigation runs. Existing data exposure can prevent independent validation even when files are available.
No verified artifact manifest is connected to this record yet. The gaps above identify what is needed before analysis can begin.
1 evaluation · 8 results. Different protocols are not a single leaderboard.
Applied filters: All linked evaluations
| Tested configuration | Protocol and dataset | Finding | Evidence and details |
|---|---|---|---|
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 43% benign_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, benign_concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 78% concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 78.2% missense_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, missense_concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 82.5% oncogene_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, oncogene_concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 79% oncogenic_vs_pathogenic_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, oncogenic_vs_pathogenic_concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 49.4% truncating_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, truncating_concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 76% tsg_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, tsg_concordance; subgroup values correspond to Supplemental Table S6 |
| Configuration: OncoVI 2026 publication configuration | Protocol: OncoVI three-class assessment: Erlangen MTB variants Dataset: Erlangen MTB variants | 97% vus_concordance percent · higher Uncertainty: Not reported Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceNot reported Aggregation: Not reported Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology · Results, Erlangen MTB variants, vus_concordance; subgroup values correspond to Supplemental Table S6 |
Source checking is not independent reproduction. Release 2026-09-30-e37e3ab1284d.
A dataset supplies biological observations. The evaluation protocol defines how those observations are split, used and scored.
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
3 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
| attributes.variants 7802 Context-only references | Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology No field-specific location recorded Version: 2026 final full text in Europe PMC XML | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| description Prior MTB effect-on-protein-function classes are a proxy reference, not oncogenicity ground truth. Context-only references | Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology No field-specific location recorded Version: 2026 final full text in Europe PMC XML | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| name Erlangen MTB variants Context-only references | Oncogenicity Variant Interpreter (OncoVI) Supports Harmonized Somatic Variant Interpretation in Precision Oncology No field-specific location recorded Version: 2026 final full text in Europe PMC XML | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
View linked audit checks and correction history
Release 2026-09-30-e37e3ab1284d · Record review: source checked
Stable ID: uc-clinical-20260930-oncovi-mtb-data